tiprankstipranks
Trending News
More News >

Chimeric Therapeutics Announces Cessation of Securities

Story Highlights
Chimeric Therapeutics Announces Cessation of Securities

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.

Chimeric Therapeutics Ltd. announced the cessation of certain securities, specifically options that expired or lapsed due to unmet conditions, totaling nearly 6 million securities. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategy and operational focus.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.06M

For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1